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Edited by Veli-Pekka LehtoAbstract Prostate cancer (PCA) is the leading cause of cancer
mortality among older men in Western countries. Epidemiolog-
ical studies have shown correlation between a lower risk of
PCA and a higher consumption of antioxidants. However, the
mechanism by which antioxidants exert their eﬀects is still
unknown. In the present study, we explored the signaling
mechanism through which unique natural antioxidant derived
from spinach extract (NAO) exerts their beneﬁcial eﬀects in the
chemoprevention of PCA using human PC3 cells. Probing into
the eﬀect of NAO and its derived polyphenols on cell-cycle G1
arrest, we found that they cause cell-cycle prolongation. NAO
and its two derived puriﬁed components exhibited a signiﬁcant
increase in the level of p21cip1 expression after 36 h of starvation,
followed by 18 h of treatment with NAO in the presence of
serum. In addition, under similar conditions, the expressed level
of Cyclin A and CDK-2 in the PC3 cells was signiﬁcantly
reduced after treatment with NAO or its puriﬁed components.
Immunoblot analysis demonstrated a signiﬁcant increase in the
hypophosphorylated form of pRb and a decrease in ppRb. NAO
and its puriﬁed derived components were found to downregulate
the protein expression of another member of the pRb family,
p107, as well as that of E2F-1. These results suggest that NAO-
induced G1 delay and cell cycle prolongation are caused by
downregulation of the protein expression of ppRb and E2F in the
human PCA cell line PC3.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Prostate cancer (PCA) is one of the most common malig-
nancies in Western societies. Risk factors include age, race,
ethnicity, hormone metabolism, and dietary factors [1,2].
The use of naturally occurring dietary agents is becoming
increasingly appreciated as an eﬀective way to manage many
types of cancer in an approach known as cancer chemopre-* Corresponding author. Fax: +972-3-6356869.
E-mail address: grossms@mail.biu.ac.il (S. Grossman).
Abbreviations: NAO, natural antioxidant; PCA, prostate cancer;
TRAMP, transgenic adenocarcinoma mouse prostate; CDK, cyclin-
dependent kinase; EGCG, epigallocathecin-3-gallate; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; CDKI,
cyclin-dependent kinase inhibitor
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doi:10.1016/j.febslet.2004.06.101vention [3–12]. Among these natural dietary agents, polyphe-
nols, a constituent of diﬀerent classes of foods and beverages,
have been intensely studied in recent years [13–23]. The eﬃcacy
of green tea polyphenols, wine antioxidant polyphenols, and
silibinin in the chemoprevention of PCA was reported
[3,24,25].
We recently published details on the isolation and charac-
terization of unique natural antioxidants (NAOs) from spinach
leaves [26,27]. This NAO contains polyphenols, which include
phenolic acids (p-coumaric acid derivatives) and the glucuronic
acid derivatives of ﬂavonoids [26]. We have shown that NAO
has antioxidative [26,27], antiproliferative [28], and anti-
inﬂammatory properties [29–33] in various biological systems.
Spinach ﬂavonoids have been shown to have strong antimu-
tagenic potential and were found beneﬁcial in a Tg.AC mouse
model [33]. Furthermore, spinach NAO has been reported to
have a protective eﬀect in various animal models for diseases
such as doxorubicin-induced cardiotoxicity [30], skin papil-
loma [31], and lipopolysaccharide-induced septic shock [29,32].
Recently, we have investigated the eﬃcacy of NAO in PCA
chemoprevention [28]. NAO was tested in the transgenic ade-
nocarcinoma mouse prostate (TRAMP) model. The eﬃcacy of
NAO was compared to that of the green tea polyphenol, epi-
gallocathecin-3-gallate (EGCG), and N-acetylcysteine (NAC).
Although signiﬁcant eﬀects were exerted on diﬀerent lobes by
the latter three antioxidants, when the most severe hyperplasia
in all four lobes of TRAMP mice was evaluated, only NAO
reduced hyperplasia at weeks 9 and 13 [28]. In addition, NAO
exhibited antiproliferative activity in DU145 and PC3 cells
[28].
In the present study, we explored the signaling mechanism
through which NAO and its derived polyphenols exert their
beneﬁcial eﬀects in the chemoprevention of PCA using human
PC3 cells (an androgen-independent and metastatic PCA cell
line). Here we demonstrate that the puriﬁed polyphenols iso-
lated from NAO attenuate the G1-to-S transition of PC3 cells
by inhibiting the expression of key elements in the cell cycle
machinery which regulate G1-to-S transition.2. Materials and methods
2.1. Materials
The human PCA cells were obtained from the American Type
Culture Collection (Manassas, VA) and cultured in RPMI-1640
medium (Biological Industries, Inc., Kibbutz Beit Haemek, Israel)blished by Elsevier B.V. All rights reserved.
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tomycin, and 0.2% amphotericin. The cells were maintained at 37 C
and 5% CO2 in a humid environment.
NAO is a brown powder. It is a water-soluble antioxidant composed
of a mixture of natural molecules extracted and puriﬁed from spinach
(Spinacia oleracea) leaves and containing mainly aromatic polyphenols
[26]. For preparation, spinach leaves were homogenized with an equal
amount of H2O (w/w). The supernatant was collected and puriﬁed by
ultraﬁltration using a 3K-pore-size membrane, and centrifuged at
20 000· g for 10 min. The supernatant was collected and used as an
NAO in this study.2.2. Cell proliferation and viability assay
The eﬀect on cell proliferation was measured by a modiﬁed 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
(Sigma, MO) assay based on the ability of live cells to cleave the
tetrazolium ring to a molecule in active mitochondria that absorb at
570 nm [34]. 5 103 PC3 cells were grown on a 96-well microliter
plate and incubated with polyphenols [glucurinated ﬂavonoids (5–20
lM) and p-coumaric acid derivatives (15–60 lM)] or NAO (0.8, 1.6,
and 3.2 mg/ml) in RPMI-10% FCS. After 24, 48, and 72 h, the
medium was changed and 130 ll/well of fresh RPMI-1640 complete
media were added. Next, 20 ll of MTT reagent (5 mg/1ml PBS) was
added to each well, and the cells were further incubated at 37 C for
2 h. To determine lysis of the cells, 100 ll of N,N-dimethyl form-
amide solution (50% ﬁnal concentration of N,N-dimethyl formamide
and 20% sodium dodecyl sulfate, pH 4.7) was added to each well
for an additional 7 h, followed by reading on a scanning multiwell
spectrophotometer.
For the trypan blue dye assay, 1 106 PC3 cells were plated in
triplicate (for each time point) into 100-mm culture dishes and treated
with NAO (0.8, 1.6, and 3.2 mg/ml) in RPMI-10% FCS for 24, 48, and
72 h. The viable cells were determined by trypan blue dye assay. The
experiment was repeated three times.
2.3. DNA cell cycle analysis
PC3 cells were grown to 70% conﬂuence, detached using a solution
of 0.1% trypsin, counted, and plated at a density of 1 106 cells in 100-
mm culture dishes. The cells were starved for 36 h (G0 phase), after
which they were treated with polyphenols [glucurinated ﬂavonoids (5–
20 lM) and p-coumaric acid derivatives (15–60 lM)] or 3.2 mg/ml
NAO, in RPMI complete medium for 8–24 h and then spun at 300 g.
The pellet was resuspended in 250 ll PBS and 1 ml ethanol for 1 h at 4
C. After centrifugation at 300· g for 5 min, the pellet was washed
twice with PBS, suspended in 400 ll of PBS and 400 ll of propidium
iodide (50 lg/ml ﬁnal concentration) for 15 min, and analyzed using
ﬂow cytometry.
2.4. Western blot analysis
The PC3 cells were grown to 70% conﬂuence, detached using a
solution of 0.1% trypsin, counted, and plated at a density of 1 106
cells in 100-mm culture dishes. The cells were starved for 36 h, after
which they were treated with puriﬁed polyphenols derived from
NAO [glucurinated ﬂavonoids (40 lM) or p-coumaric acid deriva-
tives (120 lM) or a combination of glucurinated ﬂavonoids (20 lM)
and p-coumaric acid derivatives (60 lM) in RPMI-1640 complete
media for 18 h] or with NAO (0.8, 1.6, and 3.2 mg/ml). The media
were then aspirated and the cells washed with cold PBS. The cells
were scraped and washed twice by centrifugation at 500· g for 5
min at 4 C. The pellet was resuspended in lysis buﬀer supplemented
with proteases and phosphotase inhibitors and incubated for 1 h at
4 C. The lysate was collected by centrifugation at 14 000· g for 40
min at 4 C, and the supernatant (total cell lysate) was stored at
)20 C. For Western blot analysis, 25–40 lg protein were resolved
over 7.5% or 12% polyacrylamide gels and transferred to a nitro-
cellulose membrane. The blot was blocked in blocking buﬀer (1–5%
non-fat dried milk/1% Tween 20 in PBS) for 1 h at room temper-
ature, incubated with appropriate monoclonal (human reactive anti-
p21cip1, anti-CDK-2, and anti-pRb) or polyclonal (human reactive
anti-Cyclin A, anti-p107, and E2F-1) primary antibodies in blocking
buﬀer overnight at 4 C. The blot was then incubated with anti-
mouse or anti-rabbit secondary antibody horseradish peroxidase
conjugate and detected by chemiluminescence and autoradiography
using X-ray ﬁlm.2.5. HPLC analysis and separation
The concentration of solids in the NAO supernatant was about
3%, as determined by reﬂectometry. The supernatant was concen-
trated to 25% by evaporation at 80 C. One ml of this supernatant
was mixed with 9 ml acetone AR for 5 min by stirring. This mixture
was centrifuged at 20 000· g for 10 min. The supernatant was col-
lected, and the acetone was evaporated at 85 C; this residue was
used for HPLC analysis and separation. Four compounds were










   
   3. Results
3.1. Eﬀect of puriﬁed polyphenols derived from NAO on PCA
cell proliferation and cell viability
Recently, we have elucidated the eﬃcacy of NAO in slowing
down the spontaneous tumorigenic progression in TRAMP
male mice [28]. The mechanisms involved in the chemopre-
ventive eﬀect of NAO and its puriﬁed derived components, are
not yet understood. The main goal of the present study was to
shed some light on these mechanisms using the PCA cell line
system.
The eﬀect of the puriﬁed polyphenols and the spinach ex-
tract NAO at various concentrations on cell proliferation of
human PCA cell line was studied after 24, 48, and 72 h of cell
growth (Fig. 1). It is clearly seen that in polyphenol-treated
PC3 cells, inhibition of cellular proliferation occurred in a
dose- and time-dependent manner. Similar data were obtained
with NAO (Fig. 2). These data were also supported by the
results of the trypan blue assay for studying cell viability
(Fig. 3A). The trypan blue exclusion assay demonstrates that
NAO treatment resulted in a dose- and time-dependent inhi-
bition of cell growth.
Fig. 3B shows that the inhibition of cell growth is not a
result of cell death. The relatively high proportion of dead cells
found in the control sample 48 h after seeding probably reﬂects
anoikis [35]. After 72 h, the proportion of dead cells is reduced
by more than half (data not shown).
Fig. 3. (A) Dose- and time-dependent eﬀect of NAO on PC3 cell
growth. (B) Viability of PC3 cells following NAO treatment for 48 h.
PC3 cells at 1 106 cells/dish were incubated with NAO (0.8, 1.6, and
3.2 mg/ml) in RPMI-10% FCS, and the total number of cells and the
number of viable cells were measured by trypan blue dye assay. The
data are represented as number of cells 106. Data shown are mean






















Control F-5µM + P-15µM
F-10µM + P-30µM F-20µM + P-60µM
Fig. 1. Dose- and time-dependent eﬀect of the combination of puriﬁed
compounds derived from NAO on the proliferation of human PC3 cell
line. PC3 cells at 5 103 cells/well were cultured with puriﬁed com-
pounds [glucurinated ﬂavonoids (F) (5–20 lM) and p-coumaric acid
derivatives (P) (15–60 lM)] in RPMI-10% FCS. Cell proliferation on
each day was determined by MTT assay, and experiments were ter-
minated on day 4. Each time point represents quadruplicate sam-


























Fig. 2. Dose- and time-dependent eﬀect of NAO on proliferation of
human PC3 cell line. PC3 cells at 5 103 cells/well were cultured with
NAO (0.8, 1.6, and 3.2 mg/ml) in RPMI-10% FCS. Cell proliferation
on each day was determined by MTT assay, and experiments were
terminated on day 4. Each time point represents quadruplicate samples
±S.E., and the growth curve was derived from three repeated experi-
ments.
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Since the eﬀect of the polyphenols derived from NAO on cell
proliferation may be due to cell cycle regulation, we examined
this eﬀect on cell cycle perturbations using ﬂow cytometric
analysis. The eﬀect of these antioxidants on PC3 cells was
studied after starving the cells for 36 h, followed by serum
addition. No cells were found in the sub-G1 population region
of the cell cycle, which eliminates apoptosis as a possible
mechanism of action. Moreover, the hypothesis that the pu-
riﬁed polyphenols or NAO act through apoptosis induction
was negated since no morphological alterations were detected,
as shown by confocal microscopy after either labeling cells
with acridine orange and ethidium bromide or detection with
the Annexin V Fitc (Apoptosis Detection Kit) (data not
shown).
Probing into the eﬀect of the polyphenols on cell-cycle G1
arrest, we did a time-dependent study on a synchronized
population, following the status of the cells at diﬀerent times
points after they re-entered the cell cycle. The data obtained
are presented in Figs. 4 and 5. They clearly show that the
puriﬁed spinach polyphenols inhibit the exit of the cells from
the G1 state. This phenomenon was more signiﬁcant after 18 hof treatment with NAO or its puriﬁed components. For that
reason, we focused on the 18-h treatment for further analysis.
The passage of the PC3 cells to the G1 phase was signiﬁcantly
delayed by NAO at a concentration of 3.2 mg/ml after 24 h of
treatment, as compared to the control.
3.3. Eﬀect of the polyphenols on cell protein expression
Using Western blot analysis, we next assessed the eﬀect of
NAO-derived polyphenols on the expression of proteins that
might be involved in the control of cellular proliferation. Cell
cycle progression is regulated via irreversible transitions pro-
pelled by CDKs and cyclins [36]. Therefore, we reasoned that
an observed G1 delay by the polyphenols or NAO could be
due to a decrease in kinase activity of CDKs and cyclins. CDK
activity is regulated positively by cyclins and negatively by
CDKIs [36,37]. We assessed the eﬀect of the polyphenol
treatment on cyclin-dependent kinase inhibitor (CDKI) p21cip1
level in PC3 cells. The glucurinated ﬂavonoids and p-coumaric
acid derivatives exhibited a signiﬁcant increase in the level of
p21cip1 expression after 36 h of starvation, followed by 18 h of
treatment with the puriﬁed polyphenols (Fig. 6). A similar
eﬀect was obtained with NAO (Fig. 6). In addition, we found
that under similar conditions, the expressed level of Cyclin A
and CDK-2 in the PC3 cells was signiﬁcantly reduced after
treatment with the polyphenols or NAO (Fig. 6).
Proteins from the retinoblastoma (Rb) family and from the
E2F family of transcription factors are thought to play a key
role in the regulation of G1>S phase transition in the cell cycle.
In view of the data obtained from the cytometric study of the
cell cycle, which clearly indicated a G1>S delay (Fig. 4), we
explored the possible involvement of the pRb-E2F pathway
during polyphenol-mediated cell cycle delay. It is well docu-
mented in the literature that the binding of phosphorylated
Fig. 4. Eﬀect of the puriﬁed compounds derived from NAO on cell
cycle G1 delay. A time-dependent study followed the status of the
cells after treatment with the puriﬁed compounds. PC3 cells at 1 106
cells/dish were synchronized by serum starvation for 36 h after which
they were treated with serum and a combination of the puriﬁed com-
pounds [glucurinated ﬂavonoids (20 lM) and p-coumaric acid deriv-
atives (60 lM)] for 12, 18, and 24 h and analyzed by ﬂow cytometry.
The data shown are representative of three independent experiments
with similar ﬁndings.
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tivation of members of the E2F family of transcription factors
[38]. Therefore, the eﬀect of the polyphenols and NAO on
the expression of Rb proteins in PC3 cells was assessed. The
phosphorylation of Rb proteins is an important event in the
progression of the cell cycle at G1>S transition. Immunoblot
analysis demonstrated a signiﬁcant increase in the hypo-
phosphorylated form of pRb and a decrease in ppRb (Fig. 6).
pRb is largely found in hypophosphorylated form in early G1
phase. The puriﬁed derived components and NAO were found
to downregulate the protein expression of another member of
the Rb family, p107, as well as that of E2F-1 (Fig. 6). We
demonstrated that the eﬀect of NAO treatment on the ex-
pression of several members of the cell cycle machinery in PC3
cells was dose-dependent (Fig. 7). We also studied the eﬀect of
the puriﬁed polyphenols and NAO on other proteins involved
in cell cycle regulation such as p27, cyclin D1, Cyclin E, and
CDK 4/6. We did not ﬁnd any signiﬁcant changes in the level
of these proteins due to the various treatments (data not
shown).It is clear that the polyphenol or NAO treatment signiﬁ-
cantly reduced the expression level of phosphorylated Rb
proteins. These results suggest that the polyphenol-induced G1
delay and cell cycle prolongation are caused by downregula-
tion of the protein expression of pRb and E2F in the human
PCA cell line PC3.4. Discussion
We have previously reported that an aqueous spinach leaf
extract contains a powerful system composed of NAOs, which
we named NAO [39]. Recently, the main components of NAO
were isolated, chemically analyzed, and characterized as de-
rivatives of ﬂavonoids and p-coumaric acid [26]. The biological
potential of NAO was elucidated in various in vivo and in vitro
model systems [32].
In a more recent study, we elucidated the beneﬁcial eﬀect
NAO has in preventing PCA in mice using the TRAMP model
[28]. In this model, the eﬃcacy of NAO in reducing the severity
of hyperplasia on the various prostate lobes was compared to
that of other antioxidants. NAO exerted a signiﬁcant preven-
tative eﬀect on the dorsal and lateral lobes after 9 and 13 weeks
of treatment. In addition, plasma peroxide levels in TRAMPs
were reduced following oral administration of NAO. More-
over, in NAO-treated PC3 PCA cells, inhibition of cellular
proliferation occurred.
In the present study, we focused on the eﬀect of the puriﬁed
polyphenols isolated from NAO on cell proliferation of human
PCA cell lines, and tried to elucidate the signaling mechanism
through which they exert their eﬀect. In addition, we studied,
in parallel, the eﬀect of NAO in these systems since NAO has
the potential to be used as a natural preventive combination
against PCA.
First, we discovered that in the PC3 PCA human cell line,
the inhibition of cell proliferation is dose- and time-dependent
(Figs. 1 and 2).
Since preliminary results indicated that NAO can cause G1
arrest [28], we carefully explored these pathways by following
the dependence of the cell cycle on time kinetics both with the
control and the polyphenol-treated cells (Fig. 4). This clearly
demonstrated that the puriﬁed fractions and NAO aﬀect the
proliferation of the PCA cells by prolonging the cell cycle.
Thus, they delay the mitosis of the cancer cells by increasing
the level of the cells at the G1 phase.
Pathways that link the cell cycle machinery to the tran-
scription apparatus largely control cell cycle progression.
Consequently, transcriptional components play a central role
in the regulation of the cell cycle. Members of the E2F tran-
scription factor family have been characterized as growth-
stimulating proteins [40,41]. E2F and particularly E2F-1
function to enhance cell growth by advancing quiescent cells
through G1 into S phase [40]. Typically, E2F-1 activity is in-
hibited during G1 by binding to the Rb tumor suppressor gene
product [42–44]. pRB belongs to a family of proteins desig-
nated as ‘‘pocket proteins’’ [45], which include Rb p107.
Members of this family suppress cell growth, at least in part,
by inhibiting E2F-dependent transcription of genes whose
products are required for DNA synthesis and/or cell cycle
progression [41,45]. The ability of pRb to bind E2F depends
on its phosphorylation status. Speciﬁcally, pRb is phosphor-
ylated in G0/G1 and becomes overtly hyperphosphorylated at
Fig. 5. Eﬀect of NAO on cell cycle G1 delay. A time-dependent study followed the status of the cells after NAO treatment. PC3 cells at 1 106 cells/
dish were synchronized by serum starvation for 36 h after which they were treated with serum and 3.2 mg/ml NAO for 8, 12, 18, and 24 h and
analyzed by ﬂow cytometry. The data shown are representative of three independent experiments with similar ﬁndings.
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cyclin–CDK complexes, results in the release of ‘‘free’’ E2F
and thereby activates genes required for DNA synthesis, such
as DNA polymerase and thymidine kinase [46].
Cyclin A:CDK-2 complex phosphorylates Rb and its kinase
activity is rate-limiting for entrance into the S phase [47].
Cyclins, their associated kinases (CDKs), and cyclin inhibitory
proteins like p21cip1, are integral components in the coordi-
nated progression of the cell cycle [48–50]. p21cip1 is a ubiq-
uitous inhibitor of cyclin kinases and a critical regulator of cell
cycle progression [48,50–52]. p21cip1 has been shown to inde-
pendently bind CDK-2, Cyclin A, and proliferating cell nu-
clear antigens [52].
The association of p21cip1 with Cyclin A:CDK-2 inhibits
kinase activity [50] and interferes with transcriptional activa-
tion events mediated by this complex [51,53].
The ability of the spinach polyphenols and NAO to atten-
uate G1-to-S transition is probably a consequence of their
ability to interfere with several components which regulate the
cell cycle. At the protein level, these antioxidants inhibit the
elevation of several key proteins which function in the transi-
tion from G1-to-S, including Cyclin A, CDK-2, and E2F.
Moreover, the polyphenols and NAO elevate the protein level
of p21cip1, which inhibits Cyclin A:CDK-2 activity. All to-
gether, these changes are probably responsible for sustaining
the hypophosphorylated state of pRb that is seen in cellstreated with the polyphenols or NAO. This eﬀect, together with
the reduced level of E2F protein, which is needed as an active
transcription factor at the G1/S boundary, explain the delay in
S phase entrance seen in the presence of these NAOs. Never-
theless, an as-yet unknown mechanism somehow overrides
these eﬀects since the cells do eventually enter the S phase. For
this reason, the polyphenols and NAO cause prolongation
of the cell cycle instead of G1 arrest. The mechanism by which
these natural compounds reduce the protein levels of Cyclin A,
CDK-2, or E2F is still an enigma. In order to see if NAO in-
terferes with mitogenic signals elicited by serum-derived
growth factors, we designed the experiments in a way that
enabled us to compare the mitogenic response of quiescent cells
when serum is added in the presence or absence of NAO. In
fact, serum addition caused an elevation in the expression of
Cyclin A, CDK-2, and E2F while NAO prevented this eﬀect in
a dose-dependent manner, suggesting a possible disruption of
the transduction of the mitogenic signal. One publicized study
mentioned that coumaric acid, which is one of the components
of NAO, is a tyrosine kinase inhibitor and might block the
activity of tyrosine kinase receptors [54]. Our results showed
that, besides p-coumaric acid, glucorinated ﬂavonoids were
also eﬀective, indicating that NAO activity resides in more than
one component. Recently, several studies with the antioxidant
vitamin E and the polyphenolic ﬂavonoid silibinin showed
similar results concerning their anti-proliferation eﬀects on
Fig. 6. Eﬀect of NAO and its derived puriﬁed compounds on the level
of p21cip1, Cyclin A, CDK-2, p107, pRb, and E2F-1 in PC3 cells. PC3
cells at 1 106 cells/dish were starved for 36 h, and then treated with
either NAO (3.2 mg/ml) or one of the two NAO-derived derivatives,
glucurinated ﬂavonoid (40 lM) and p-coumaric acid (120 lM) or the
combination of glucurinated ﬂavonoids (20 lM) and p-coumaric acid
derivatives (60 lM), in complete media for 18 h. Total cell lysates were
prepared, and 40 lg protein was subjected to SDS–PAGE, followed by
immunoblot analysis. The data shown are representative of three
independent experiments with similar ﬁndings.
Fig. 7. Dose-dependent eﬀect of NAO treatment on the expression of a
number of key members of the cell cycle machinery in PC3 cells. PC3
cells at 1 106 cells/dish were starved for 36 h, and then treated with
NAO (0.8, 1.6, and 3.2 mg/ml) in complete media for 18 h. Total cell
lysates were prepared, and 40 lg protein was subjected to SDS–PAGE,
followed by immunoblot analysis. The data shown are representative
of three independent experiments with similar ﬁndings.
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hypophosphorylated form of pRb at the expense of the phos-
phorylated form of Rb, reduction at the protein level of CDKs,
and cyclin typical to G1 phase of the cell cycle together with
enhanced expression of the CDK inhibitor p21cip1 [55–57].
EGCG, a polyphenol derived from green tea, was recently
reported as aﬀecting the expression level of diﬀerent E2F iso-
forms leading to G1 arrest and apoptosis. These activities re-
semble our results, but diﬀer in the ﬁnal outcome, where,
unlike EGCG, the NAO-derived polyphenols attenuate rather
than arrest growth and do not culminate in apoptosis. A
possible explanation for the diﬀerence between the NAO-de-
rived polyphenols and EGCG with regard to the induction of
apoptosis may lie in the dissimilar eﬀects that these two sub-
stances have on E2F-1 expression. While EGCG had only a
minor eﬀect on the protein level of E2F-1 [4], NAO-derived
polyphenols caused a steep reduction in the E2F-1 protein
level. E2F-1, besides being involved in G1-to-S transition,
plays a role in apoptosis by enhancing, at transcription level,
the expression of caspases; so that E2F-1 directly couples the
cell cycle with the cell death machinery [58]. Therefore, inhi-
bition of E2F-1 expression by NAO-derived polyphenols
might partially explain the absence of apoptosis in NAO-de-
rived polyphenol-treated cells. The absence of the apoptotic
response in cells treated with NAO was also validated by
testing NAO-treated cells for apoptotic response using theAnnexin V Fitc-based apoptosis detection kit (data not
shown).
Prolongation of the cell cycle by the natural polyphenols or
NAO might provide several beneﬁts in terms of tumor eradi-
cation or prevention. First, it reduces the amount of cell dou-
bling and, through this, might decrease the number of genetic
changes acquired by tumor cells with time. Second, a lowered
rate of proliferation minimizes tumor size, helping the immune
system in its eﬀort to eradicate the tumor. Many tumors are
lethal due to the fact that they develop in an aggressive manner,
killing their host in a short time period. Attenuation of growth
might convert those tumors from acute to chronic and prolong
the life expectancy of the patients. Third, the fact that the po-
lyphenols or NAO did not induce apoptosis suggests that it will
not harm healthy, normal cells. Taken together, the above-
mentioned properties qualify NAO as a potential chemopre-
ventive agent, which might also be beneﬁcial in treating existing
tumors alone or in combination with other chemotherapeutic
agents. Systemic research on NAO eﬀects on a battery of dif-
ferent human tumors is now being performed.
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